Epithelial-mesenchymal crosstalk alteration in kidney fibrosis

Journal of Pathology

Volumn 228, Issue 2, 2012, Pages 131-147

  Prunotto, Marco ^a   Budd, David C ^b   Gabbiani, Giulio ^c   Meier, Matthias ^a   Formentini, Ivan ^a   Hartmann, Guido ^a   Pomposiello, Silvia ^a   Moll, Solange ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

crosstalk; epithelium; fibrosis; kidney; mesenchyme; microenvironment; renin angiotensin system

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; CADHERIN; CADHERIN 9; CALVASCULIN; CD37 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 7; CONNECTIVE TISSUE GROWTH FACTOR; CYCLINE; ECTO 5 NUCLEOTIDASE; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GAMMA INTERFERON; GUANYLATE CYCLASE; INTERLEUKIN 1; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NOTCH RECEPTOR; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; TENASCIN; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ALBUMINURIA; APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CHRONIC KIDNEY DISEASE; CREATININE URINE LEVEL; DISEASE COURSE; DNA REPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE EXPRESSION; GLOMERULOSCLEROSIS; HUMAN; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE BASEMENT MEMBRANE; MICROENVIRONMENT; MOLECULAR INTERACTION; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ULTRAFILTRATION;

CELL COMMUNICATION; CELLULAR MICROENVIRONMENT; DISEASE PROGRESSION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEEDBACK, PHYSIOLOGICAL; FIBROSIS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MESODERM; RENIN-ANGIOTENSIN SYSTEM;

EID: 84866255883     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4049     Document Type: Review

References (201)

1. Turner JM, Bauer C, Abramowitz MK, et al., Treatment of chronic kidney disease. Kidney Int 2012; 81: 351-362.
2. Onuigbo MA,. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin Pract 2011; 118: c407-419.
3. Ruggenenti P, Perticucci E, Cravedi P, et al., Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213-1224.
4. Rosolowsky ET, Skupien J, Smiles AM, et al., Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22: 545-553.
5. Bohle A, Muller GA, Wehrmann M, et al., Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int 1996; 54: S2-9.
6. Eddy AA, Neilson EG,. Chronic kidney disease progression. J Am Soc Nephrol 2006; 17: 2964-2966.
7. Fine LG, Ong AC, Norman JT,. Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur J Clin Invest 1993; 23: 259-265.
8. Zeisberg M, Neilson EG,. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834.
9. Lewis MP, Fine LG, Norman JT,. Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. Kidney Int 1996; 49: 48-58.
10. Johnson DW, Saunders HJ, Baxter RC, et al., Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998; 54: 747-757.
11. Abbate M, Zoja C, Rottoli D, et al., Proximal tubular cells promote fibrogenesis by TGFβ1-mediated induction of peritubular myofibroblasts. Kidney Int 2002; 61: 2066-2077.
12. 2/M mediates kidney fibrosis after injury. Nature Med 2010; 16: 535-543.
13. Udo K, Aoki S, Uchihashi K, et al., Adipose tissue explants and MDCK cells reciprocally regulate their morphogenesis in coculture. Kidney Int 2010; 78: 60-68.
14. Fine LG, Norman JT, Ong A,. Cell-cell cross-talk in the pathogenesis of renal interstitial fibrosis. Kidney Int 1995; 49: S48-50.
15. Alpers CE, Hudkins KL, Floege J, et al., Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 1994; 5: 201-209.
16. Coca SG, Yusuf B, Shlipak MG, et al., Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 53: 961-973.
17. Venkatachalam MA, Griffin KA, Lan R, et al., Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol 2010; 298: 1078-1094.
18. Amdur RL, Chawla LS, Amodeo S, et al., Outcomes following diagnosis of acute renal failure in US veterans: focus on acute tubular necrosis. Kidney Int 2009; 76: 1089-1097.
19. Ishani A, Xue JL, Himmelfarb J, et al., Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
20. Lo LJ, Go AS, Chertow GM, et al., Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 2009; 76: 893-899.
21. Wald R, Quinn RR, Luo J, et al., Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. J Am Med Assoc 2009; 302: 1179-1185.
22. Chawla LS, Amdur RL, Amodeo S, et al., The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79: 1361-1369.
23. Ali T, Khan I, Simpson W, et al., Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298.
24. Hsu CY, McCulloch CE, Fan D, et al., Community-based incidence of acute renal failure. Kidney Int 2007; 72: 208-212.
25. Hou SH, Bushinsky DA, Wish JB, et al., Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243-248.
26. http://www.usrds.org/2006/ref/A-incidence-06.pdf.
27. Risdon RA, Sloper JC, De Wardener HE,. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
28. Schainuck LI, Striker GE, Cutler RE, et al., Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1970; 1: 631-641.
29. Harris RC, Neilson EG,. Toward a unified theory of renal progression. Annu Rev Med 2006; 57: 365-380.
30. Farris AB, Adams CD, Brousaides N, et al., Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 2011; 22: 176-186.
31. Alexakis C, Maxwell P, Bou-Gharios G,. Organ-specific collagen expression: implications for renal disease. Nephron 2006; 102: e71-75.
32. Eddy AA,. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
33. Bohle A, Christ H, Grund KE, et al., The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 1979; 16: 109-114.
34. Neilson EG, McCafferty E, Feldman A, et al., Spontaneous interstitial nephritis in kdkd mice. I. An experimental model of autoimmune renal disease. J Immunol 1984; 133: 2560-2565.
35. Tomasek JJ, Gabbiani G, Hinz B, et al., Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev 2002; 3: 349-363.
36. Hinz B, Phan SH, Thannickal VJ, et al., The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816.
37. Wynn TA,. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
38. Zeisberg M, Duffield JS,. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2011; 21: 1247-1253.
39. Quan TE, Cowper SE, Bucala R,. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8: 145-150.
40. Gabbiani G, Ryan GB, Majne G,. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971; 27: 549-550.
41. Humphreys BD, Lin SL, Kobayashi A, et al., Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
42. Piera-Velazquez S, Li Z, Jimenez SA,. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 179: 1074-1080.
43. Zeisberg EM, Potenta SE, Sugimoto H, et al., Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287.
44. Lin SL, Kisseleva T, Brenner DA, et al., Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617-1627.
45. Humphreys BD, Lin SL, Kobayashi A, et al., Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97.
46. Picard N, Baum O, Vogetseder A, et al., Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem Cell Biol 2008; 130: 141-155.
47. Fragiadaki M, Mason RM,. Epithelial-mesenchymal transition in renal fibrosis-evidence for and against. Int J Exp Pathol 2011; 92: 143-150.
48. Kriz W, Kaissling B, Le Hir M,. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468-474.
49. Wolf G, Neilson EG,. Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int 1991; 39: 401-420.
50. Qi W, Chen X, Poronnik P, et al., The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol 2006; 38: 1-5.
51. Heidland A, Klassen A, Fazeli G, et al., Karl Peter's fundamental contribution to the structural organization of the kidney. J Nephrol 2011; 24 (suppl 17): S51-57.
52. Valtin H,. Structural and functional heterogeneity of mammalian nephrons. Am J Physiol 1977; 233: F491-501.
53. Kreidberg JA, Symons JM,. Integrins in kidney development, function, and disease. Am J Physiol 2000; 279: F233-242.
54. Erickson AC, Couchman Jr,. Still more complexity in mammalian basement membranes. J Histochem Cytochem 2000; 48: 1291-1306.
55. Paulsson M,. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992; 27: 93-127.
56. Lemley KV, Kriz W,. Anatomy of the renal interstitium. Kidney Int 1991; 39: 370-381.
57. Kaissling B, Le Hir M,. The renal cortical interstitium: morphological and functional aspects. Histochem Cell Biol 2008; 130: 247-262.
58. Rouget C,. Memoire sur le developpement, la structure et les proprietes physiologiques des capillaires sanguins et lymphatiques. Arch Physiol Norm Path 1873; 5: 603-663.
59. Courtoy PJ, Boyles J,. Fibronectin in the microvasculature: localization in the pericyte-endothelial interstitium. J Ultrastruct Res 1983; 83: 258-273.
60. Grgic I, Duffield JS, Humphreys BD,. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2012; 27: 183-193.
61. Rodemann HP, Muller GA,. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991; 17: 684-686.
62. Chang HY, Chi JT, Dudoit S, et al., Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002; 99: 12877-12882.
63. Simian M, Hirai Y, Navre M, et al., The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development (Camb. UK) 2001; 128: 3117-3131.
64. Alvarez RJ, Sun MJ, Haverty TP, et al., Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int 1992; 41: 14-23.
65. Okada H, Kalluri R,. Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 2005; 5: 467-474.
66. 2/M mediates kidney fibrosis after injury. Nat Med 16: 535-543.
67. Bielesz B, Sirin Y, Si H, et al., Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 120: 4040-4054.
68. Furuichi K, Kaneko S, Wada T,. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009; 13: 9-14.
69. Schlondorff DO,. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 2008; 74: 860-866.
70. Zeisberg M, Strutz F, Muller GA,. Renal fibrosis: an update. Curr Opin Nephrol Hypertens 2001; 10: 315-320.
71. Wang S, LaPage J, Hirschberg R,. Proteinuria and progression of chronic renal disease. Kidney Blood Pressure Res 2000; 23: 167-169.
72. Ferguson MW, O'Kane S,. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Phil Trans R Soc Lond B Biol Sci 2004; 359: 839-850.
73. Johnston JR, Brenner BM, Hebert SC,. Uninephrectomy and dietary protein affect fluid absorption in rabbit proximal straight tubules. Am J Physiol 1987; 253: F222-233.
74. Kobayashi S, Venkatachalam MA,. Differential effects of calorie restriction on glomeruli and tubules of the remnant kidney. Kidney Int 1992; 42: 710-717.
75. Abbate M, Zoja C, Remuzzi G,. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974-2984.
76. Megyesi J, Price PM, Tamayo E, et al., The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 1999; 96: 10830-10835.
77. Liu Y, Martindale JL, Gorospe M, et al., Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 1996; 56: 31-35.
78. Allan LA, Duhig T, Read M, et al., The p21(WAF1/CIP1) promoter is methylated in Rat-1 cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene. Mol Cell Biol 2000; 20: 1291-1298.
79. 1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
80. Nath KA, Croatt AJ, Haggard JJ, et al., Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int 2000; 57: 2423-2433.
81. Fragiadaki M, Witherden AS, Kaneko T, et al., Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo. Matrix Biology J Int Soc Matrix Biol 2011; 30: 396-403.
82. Rastaldi MP, Ferrario F, Giardino L, et al., Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137-146.
83. Tapp DC, Wortham WG, Addison JF, et al., Food restriction retards body growth and prevents end-stage renal pathology in remnant kidneys of rats regardless of protein intake. Lab Invest J Tech Methods Pathol 1989; 60: 184-195.
84. Nicholson ML, McCulloch TA, Harper SJ, et al., Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 1996; 83: 1082-1085.
85. Hertig A, Anglicheau D, Verine J, et al., Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584-1591.
86. Vongwiwatana A, Tasanarong A, Rayner DC, et al., Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transpl 2005; 5: 1367-1374.
87. Muramatsu M, Miyagi M, Ishikawa Y, et al., Estimation of damaged tubular epithelium in renal allografts by determination of vimentin expression. Int J Urol 2004; 11: 954-962.
88. Ward JM, Stevens JL, Konishi N, et al., Vimentin metaplasia in renal cortical tubules of preneoplastic, neoplastic, aging, and regenerative lesions of rats and humans. Am J Pathol 1992; 141: 955-964.
89. Grone HJ, Weber K, Grone E, et al., Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the kidney. Am J Pathol 1987; 129: 1-8.
90. Witzgall R, Brown D, Schwarz C, et al., Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994; 93: 2175-2188.
91. Wrighton KH, Lin X, Feng XH,. Phospho-control of TGFβ superfamily signaling. Cell Res 2009; 19: 8-20.
92. Bottinger EP, Bitzer M,. TGFβ signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-2610.
93. Hills CE, Squires PE,. The role of TGFβ and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 2011; 22: 131-139.
94. Nyhan KC, Faherty N, Murray G, et al., Jagged/Notch signalling is required for a subset of TGFβ1 responses in human kidney epithelial cells. Biochim Biophys Acta 2010; 1803: 1386-1395.
95. Sun Y, Koo S, White N, et al., Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004; 32: e188.
96. Krupa A, Jenkins R, Luo DD, et al., Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438-447.
97. Chung AC, Huang XR, Meng X, et al., miR-192 mediates TGFβ/Smad3- driven renal fibrosis. J Am Soc Nephrol 2010; 21: 1317-1325.
98. Wang B, Komers R, Carew R, et al., Suppression of microRNA-29 expression by TGFβ1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012; 23: 252-265.
99. Massague J, Blain SW, Lo RS,. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
100. Ziyadeh FN,. Role of transforming growth factor-β in diabetic nephropathy. Exp Nephrol 1994; 2: 137.
101. Shi Y, Massague J,. Mechanisms of TGFβ signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
102. Massague J,. How cells read TGFβ signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
103. Abreu JG, Ketpura NI, Reversade B, et al., Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF β. Nat Cell Biol 2002; 4: 599-604.
104. Bornstein P,. Matricellular proteins: an overview. J Cell Commun Signal 2009; 3: 163-165.
105. Perbal B,. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-64.
106. Kothapalli D, Frazier KS, Welply A, et al., Transforming growth factor-β induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ 1997; 8: 61-68.
107. Phanish MK, Winn SK, Dockrell ME,. Connective tissue growth factor (CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 2010; 114: e83-92.
108. Tu Z, Shi Y, Wang J, et al., Upregulation of connective tissue growth factor in a rat model of chronic allograft nephropathy. Nephrology 2007; 12: 166-171.
109. Okada H, Kikuta T, Kobayashi T, et al., Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005; 16: 133-143.
110. Guha M, Xu ZG, Tung D, et al., Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 2007; 21: 3355-3368.
111. Nguyen TQ, Goldschmeding R,. Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm Res 2008; 25: 2416-2426.
112. Gould SE, Day M, Jones SS, et al., BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002; 61: 51-60.
113. Simon M, Maresh JG, Harris SE, et al., Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol 1999; 276: F382-389.
114. Zeisberg M, Muller GA, Kalluri R,. Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrol Dialysis Transpl 2004; 19: 759-761.
115. Wang SN, Lapage J, Hirschberg R,. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2392-2399.
116. Vukicevic S, Basic V, Rogic D, et al., Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102: 202-214.
117. Morrissey J, Hruska K, Guo G, et al., Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 2002; 13 (suppl 1): S14-21.
118. Manson SR, Niederhoff RA, Hruska KA, et al., Endogenous BMP-7 is a critical molecular determinant of the reversibility of obstruction-induced renal injuries. Am J Physiol Renal Physiol 2011; 301: F1293-1302.
119. Hruska KA, Guo G, Wozniak M, et al., Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 2000; 279: F130-143.
120. Tanaka M, Asada M, Higashi AY, et al., Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 120: 768-777.
121. Yanagita M, Okuda T, Endo S, et al., Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest 2006; 116: 70-79.
122. Tanaka M, Endo S, Okuda T, et al., Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int 2008; 73: 181-191.
123. Flier SN, Tanjore H, Kokkotou EG, et al., Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.
124. Dudas PL, Argentieri RL, Farrell FX,. BMP-7 fails to attenuate TGFβ1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells. Nephrol Dialysis Transpl 2009; 24: 1406-1416.
125. Wang S, de Caestecker M, Kopp J, et al., Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17: 2504-2512.
126. Sharma S, Sirin Y, Susztak K,. The story of Notch and chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 56-61.
127. Bielesz B, Sirin Y, Si H, et al., Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010; 120: 4040-4054.
128. Surendran K, Schiavi S, Hruska KA,. Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005; 16: 2373-2384.
129. Surendran K, McCaul SP, Simon TC,. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol 2002; 282: F431-441.
130. He W, Dai C, Li Y, et al., Wnt/β-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765-776.
131. Ding H, Zhou D, Hao S, et al., Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol 2012; 23: 801-813.
132. Heintzman ND, Stuart RK, Hon G, et al., Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39: 311-318.
133. Bannister AJ, Kouzarides T,. Regulation of chromatin by histone modifications. Cell Res 2011; 21: 381-395.
134. Zager RA, Johnson AC,. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/profibrotic genes. Am J Physiol 2009; 296: F1032-1041.
135. Zager RA, Johnson AC, Becker K,. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and 'end-stage' kidney disease. Am J Physiol Renal Physiol 2011; 301: F1334-1345.
136. Marumo T, Hishikawa K, Yoshikawa M, et al., Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 2010; 298: F133-141.
137. Noh H, Oh EY, Seo JY, et al., Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-β1-induced renal injury. Am J Physiol Renal Physiol 2009; 297: F729-739.
138. Hu B, Gharaee-Kermani M, Wu Z, et al., Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am J Pathol 2010; 177: 21-28.
139. Levey AS, Cattran D, Friedman A, et al., Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-226.
140. Fassett RG, Venuthurupalli SK, Gobe GC, et al., Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821.
141. Fagerudd JA, Groop PH, Honkanen E, et al., Urinary excretion of TGFβ1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients. Kidney Int Suppl 1997; 63: S195-197.
142. Gilbert RE, Akdeniz A, Weitz S, et al., Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003; 26: 2632-2636.
143. Mishra J, Dent C, Tarabishi R, et al., Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
144. Bolignano D, Lacquaniti A, Coppolino G, et al., Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Pressure Res 2009; 32: 91-98.
145. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, et al., Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transpl Proc 2009; 41: 158-161.
146. Kamijo A, Sugaya T, Hikawa A, et al., Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145: 125-133.
147. Nielsen SE, Sugaya T, Hovind P, et al., Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010; 33: 1320-1324.
148. Herget-Rosenthal S,. Imaging techniques in the management of chronic kidney disease: current developments and future perspectives. Semin Nephrol 2011; 31: 283-290.
149. Chevalier RL, Kim A, Thornhill BA, et al., Recovery following relief of unilateral ureteral obstruction in the neonatal rat. Kidney Int 1999; 55: 793-807.
150. Koo JW, Kim Y, Rozen S, et al., Enalapril accelerates remodeling of the renal interstitium after release of unilateral ureteral obstruction in rats. J Nephrol 2003; 16: 203-209.
151. Adamczak M, Gross ML, Krtil J, et al., Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14: 2833-2842.
152. Ma LJ, Nakamura S, Aldigier JC, et al., Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976.
153. Gilbert RE, Cox A, Wu LL, et al., Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998; 47: 414-422.
154. Remuzzi A, Fassi A, Bertani T, et al., ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis 1999; 34: 626-632.
155. Zoja C, Corna D, Camozzi D, et al., How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13: 2898-2908.
156. Fogo AB,. Regression lines in chronic kidney disease. J Am Soc Nephrol 2003; 14: 2990-2991.
157. Ruiz-Ortega M, Egido J,. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52: 1497-1510.
158. Wolf G, Killen PD, Neilson EG,. Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 1991; 2: 219-227.
159. Brown NJ, Vaughan DE, Fogo AB,. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 2002; 22: 399-406.
160. Levin A, Beaulieu MC,. Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. J Am Soc Nephrol 2011; 22: 992-993.
161. Fioretto P, Sutherland DE, Najafian B, et al., Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69: 907-912.
162. Cordonnier DJ, Pinel N, Barro C, et al., Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 1999; 10: 1253-1263.
163. Langham RG, Kelly DJ, Gow RM, et al., Transforming growth factor-β in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 2006; 29: 2670-2675.
164. Shin GT, Kim SJ, Ma KA, et al., ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 2000; 36: 894-902.
165. Choi SJ, Kim JK, Hwang SD,. Mesenchymal stem cell therapy for chronic renal failure. Exp Opin Biol Ther 2010; 10: 1217-1226.
166. Camussi G, Deregibus MC, Tetta C,. Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information. Curr Opin Nephrol Hypertens 2010; 19: 7-12.
167. Togel FE, Westenfelder C,. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183.
168. Shihab FS, Bennett WM, Yi H, et al., Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transpl 2002; 2: 111-119.
169. Cho ME, Kopp JB,. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs 2010; 19: 275-283.
170. Cho ME, Smith DC, Branton MH, et al., Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913.
171. Sharma K, Ix JH, Mathew AV, et al., Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22: 1144-1151.
172. Fogo AB, Alpers CE,. Navigating the challenges of fibrosis assessment: land in sight? J Am Soc Nephrol 2011; 22: 11-13.
173. Young L, Adamson IY,. Epithelial-fibroblast interactions in bleomycin-induced lung injury and repair. Environ Health Perspect 1993; 101: 56-61.
174. Khalil N, O'Connor RN, Unruh HW, et al., Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Resp Cell Mol Biol 1991; 5: 155-162.
175. Antoniades HN, Bravo MA, Avila RE, et al., Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055-1064.
176. Nash JR, McLaughlin PJ, Butcher D, et al., Expression of tumour necrosis factor-α in cryptogenic fibrosing alveolitis. Histopathology 1993; 22: 343-347.
177. Selman M, Pardo A,. The epithelial-fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Resp Cell Mol Biol 2003; 29: S93-97.
178. Kuwano K, Hagimoto N, Kawasaki M, et al., Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104: 13-19.
179. Canbay A, Higuchi H, Bronk SF, et al., Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-1330.
180. Kinnman N, Housset C,. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 2002; 7: d496-503.
181. Desmouliere A, Guyot C, Gabbiani G,. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004; 48: 509-517.
182. De Wever O, Mareel M,. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-447.
183. Faouzi S, Le Bail B, Neaud V, et al., Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol 1999; 30: 275-284.
184. Shao ZM, Nguyen M, Barsky SH,. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000; 19: 4337-4345.
185. Silzle T, Randolph GJ, Kreutz M, et al., The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004; 108: 173-180.
186. Dawson TP, Gandhi R, Le Hir M, et al., Ecto-5'-nucleotidase: localization in rat kidney by light microscopic histochemical and immunohistochemical methods. J Histochem Cytochem 1989; 37: 39-47.
187. Thedieck C, Kalbacher H, Kuczyk M, et al., Cadherin-9 is a novel cell surface marker for the heterogeneous pool of renal fibroblasts. PLoS One 2007; 2: e657.
188. Theilig F, Bostanjoglo M, Pavenstadt H, et al., Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. J Am Soc Nephrol 2001; 12: 2209-2220.
189. Ryan GB, Cliff WJ, Gabbiani G, et al., Myofibroblasts in human granulation tissue. Hum Pathol 1974; 5: 55-67.
190. Oldroyd SD, Thomas GL, Gabbiani G, et al., Interferon-γ inhibits experimental renal fibrosis. Kidney Int 1999; 56: 2116-2127.
191. Strutz F, Okada H, Lo CW, et al., Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405.
192. Brisset AC, Hao H, Camenzind E, et al., Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Circ Res 2007; 100: 1055-1062.
193. Osterreicher CH, Penz-Osterreicher M, Grivennikov SI, et al., Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci USA 2011; 108: 308-313.
194. Le Hir M, Hegyi I, Cueni-Loffing D, et al., Characterization of renal interstitial fibroblast-specific protein 1/S100A4-positive cells in healthy and inflamed rodent kidneys. Histochem Cell Biol 2005; 123: 335-346.
195. Ng YY, Huang TP, Yang WC, et al., Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998; 54: 864-876.
196. Fan JM, Ng YY, Hill PA, et al., Transforming growth factor-β regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999; 56: 1455-1467.
197. Iwano M, Plieth D, Danoff TM, et al., Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
198. Zeisberg M, Hanai J, Sugimoto H, et al., BMP-7 counteracts TGFβ1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
199. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al., Epithelial-to- mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 2008; 19: 1571-1583.
200. Li L, Zepeda-Orozco D, Black R, et al., Autophagy is a component of epithelial cell fate in obstructive uropathy. Am J Pathol 2010; 176: 1767-1778.
201. Koesters R, Kaissling B, Lehir M, et al., Tubular overexpression of transforming growth factor-β1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010; 177: 632-643.